Literature DB >> 26086931

Strategies for the Discovery of Target-Specific or Isoform-Selective Modulators.

Peng Zhan1, Yukihiro Itoh2, Takayoshi Suzuki2,3, Xinyong Liu1.   

Abstract

Currently, the creation of class- and isoform-selective modulators of biologically important targets is a particularly challenging problem because different isoforms within a protein family often show striking similarity in spatial quaternary structure, especially at the catalytic sites or binding pockets. Therefore, an understanding of both the precise three-dimensional structure of the target protein and the mechanisms of action of modulators is important for developing more effective and selective agents. In this Perspective, we discuss currently available rational design strategies for obtaining class- and isoform-selective inhibitors and we illustrate these strategies with the aid of specific examples from the recent literature. The strategies covered include: (1) target-derived (-dependent) de novo drug discovery methodologies, and (2) follow-on derivatization approaches from initially identified active molecules (hit-to-lead and lead-to-candidate efforts). We also comment on prospects for further development and integration of strategies to achieve target-specific or isoform-selective inhibition.

Mesh:

Substances:

Year:  2015        PMID: 26086931     DOI: 10.1021/acs.jmedchem.5b00229

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  7 in total

1.  Class I HDAC Inhibitors Display Different Antitumor Mechanism in Leukemia and Prostatic Cancer Cells Depending on Their p53 Status.

Authors:  Xiaoyang Li; Yuri K Peterson; Elizabeth S Inks; Richard A Himes; Jiaying Li; Yingjie Zhang; Xiujie Kong; C James Chou
Journal:  J Med Chem       Date:  2018-03-09       Impact factor: 7.446

2.  The increasing impact of Chinese innovative drug research on the global stage with a focus on drug discovery.

Authors:  Wei Luo; Cherukupalli Srinivasulu; Xia Hao; Xinyong Liu; Peng Zhan
Journal:  Expert Opin Drug Discov       Date:  2020-06-17       Impact factor: 6.098

3.  Surface Binding Energy Landscapes Affect Phosphodiesterase Isoform-Specific Inhibitor Selectivity.

Authors:  Qing Liu; Andreas Herrmann; Qiang Huang
Journal:  Comput Struct Biotechnol J       Date:  2018-12-28       Impact factor: 7.271

4.  Synthesis, Molecular Docking and Biological Characterization of Pyrazine Linked 2-Aminobenzamides as New Class I Selective Histone Deacetylase (HDAC) Inhibitors with Anti-Leukemic Activity.

Authors:  Hany S Ibrahim; Mohamed Abdelsalam; Yanira Zeyn; Matthes Zessin; Al-Hassan M Mustafa; Marten A Fischer; Patrik Zeyen; Ping Sun; Emre F Bülbül; Anita Vecchio; Frank Erdmann; Matthias Schmidt; Dina Robaa; Cyril Barinka; Christophe Romier; Mike Schutkowski; Oliver H Krämer; Wolfgang Sippl
Journal:  Int J Mol Sci       Date:  2021-12-29       Impact factor: 5.923

5.  Target Design of Novel Histone Deacetylase 6 Selective Inhibitors with 2-Mercaptoquinazolinone as the Cap Moiety.

Authors:  Hue Thi Buu Bui; Phuong Hong Nguyen; Quan Minh Pham; Hoa Phuong Tran; De Quang Tran; Hosun Jung; Quang Vinh Hong; Quoc Cuong Nguyen; Quy Phu Nguyen; Hieu Trong Le; Su-Geun Yang
Journal:  Molecules       Date:  2022-03-28       Impact factor: 4.411

Review 6.  Next-generation of selective histone deacetylase inhibitors.

Authors:  Feifei Yang; Na Zhao; Di Ge; Yihua Chen
Journal:  RSC Adv       Date:  2019-06-24       Impact factor: 4.036

7.  JAK inhibitors impair GM-CSF-mediated signaling in innate immune cells.

Authors:  Yuya Fujita; Naoki Matsuoka; Jumpei Temmoku; Makiko Furuya-Yashiro; Tomoyuki Asano; Shuzo Sato; Haruki Matsumoto; Hiroshi Watanabe; Hideko Kozuru; Hiroshi Yatsuhashi; Atsushi Kawakami; Kiyoshi Migita
Journal:  BMC Immunol       Date:  2020-06-15       Impact factor: 3.615

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.